{
  "ticker": "1AI",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973641",
  "id": "02973641",
  "pages": 9,
  "price_sensitive": true,
  "date": "20250729",
  "time": "0840",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m7mvx4fw2nzy.pdf",
  "summary": "### **Quarterly Report (Appendix 4C) Summary**  \n\n#### **Key Operational/Financial Highlights:**  \n- **R&D Collaboration:** Strategic partnership with Peter MacCallum Cancer Centre for preclinical validation of 21 AI-predicted drug combinations across four cancer types (brain, pancreas, breast, prostate). Results expected within six months.  \n- **AlgoraeOS v2.0 Development:** On track for Q3 2025 release, featuring multi-GPU processing, enhanced AI modeling, and multi-modal data integration.  \n- **Therapeutic Pipeline:**  \n  - **AI-116 (Dementia):** PCT patent application filed; preclinical efficacy superior to Donepezil.  \n  - **AI-168 (Cardiovascular):** Advanced formulation post-positive preclinical results.  \n- **R&D Tax Incentive:** Received **$318,771** rebate for FY2025.  \n\n#### **Financial Position:**  \n- **Cash Balance (30 June 2025):** **$2.32M**  \n- **Quarterly Net Cash Outflow:** **$264,504** (R&D spend: **$476,265**)  \n- **Estimated Funding Runway:** **8.8 quarters** (based on current burn rate).  \n\n#### **Corporate Updates:**  \n- Appointment of Chief Commercial Officer (Vishal Shah) to drive partnerships.  \n- Executive Chairman\u2019s salary adjusted to **$220k p.a.**  \n\n---  \n**Omitted:** Routine director payments, forward-looking statements, boilerplate.  \n**Materiality Focus:** Progress in AI platform, pipeline catalysts, and liquidity position.",
  "usage": {
    "prompt_tokens": 5065,
    "completion_tokens": 333,
    "total_tokens": 5398,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-28T22:56:13.066653"
}